BioCardia Announces $4.4 Million Financing
Jun 8, 2026 · Source: globenewswire.com · Topic:
institutional-equities · venture-startup-funding · fintech
Financing Amount
$4.4M
Total amount raised in the recent financing round.
Shares Sold
3,509,604 shares
Number of shares sold during the financing.
Average Share Price
$1.279
Average price per share at which the financing was executed.
§ 01 Executive Snapshot
- What: BioCardia announces a $4.4 million financing round to extend its cash runway.
- Who: BioCardia, Inc., a leader in cellular therapeutics for cardiovascular and pulmonary diseases.
- Why it matters: This financing is expected to support the company's operational plans and assist in the anticipated regulatory submission in Japan, crucial for future commercial sales.
§ 02 Key Developments
- BioCardia sold 3,509,604 shares at an average price of $1.279 on June 5, 2026.
- Net proceeds are expected to extend cash runway into the first quarter of 2027.
- Anticipated Japan PMDA submission for CardiAMP HF is set for Q4 2026.
§ 03 Strategic Context
- BioCardia has a history of developing innovative cell therapies for treating severe cardiovascular conditions, with multiple clinical-stage candidates.
- The financing aligns with broader trends in the biotech industry where companies are seeking funds to support clinical trials and regulatory submissions.
§ 04 Strategic Implications
- Immediate implications include enhanced liquidity to fund ongoing clinical trials and operational activities, positioning the company for regulatory approval.
- Long-term implications could lead to successful market entry with its therapeutics, potentially increasing its valuation and market presence in the healthcare sector.
§ 05 Risks & Constraints
- Potential risks include the company's ability to raise additional funds and the successful progression of its clinical trials, which may affect future operations.
- Regulatory uncertainties surrounding the PMDA submission may pose execution roadblocks affecting timelines.
§ 06 Watchlist / Forward Signals
- Upcoming catalysts include the publication of the CardiAMP HF manuscript and the Japan PMDA submission in Q4 2026.
- Future developments will signal success or failure, particularly regarding regulatory approvals and commercial sales timelines.
§ 07
Frequently Asked Questions
What is the purpose of BioCardia's $4.4 million financing?
The financing is intended to extend the company's cash runway and support its operational plans, including an anticipated regulatory submission in Japan.
Who is BioCardia and what do they specialize in?
BioCardia, Inc. is a leader in cellular therapeutics focused on treating cardiovascular and pulmonary diseases.
When is BioCardia planning to submit its CardiAMP HF to Japan's PMDA?
The anticipated submission for CardiAMP HF is set for Q4 2026.
§ 08
Related Articles
Trading Places: JPMorgan boosts sponsors team, ex-Eisler partner heads to Gemcorp
§ 01 Executive Snapshot What: JPMorgan expands its sponsors team and a former Eisler partner joins G
fnlondon.com
BOC Survey: Balance of opinion on indicators of future sales +15 down from +24 in Q1
§ 01 Executive Snapshot What: The Bank of Canada's Q2 survey indicates a decline in the balance of o
investinglive.com
Fed;s Waller: Forward guidance can be a valuable tool that has strengthened policymaking
§ 01 Executive Snapshot What: Fed's Waller discusses the value and risks of forward guidance in mone
investinglive.com
Bitcoin moves into negative territory and back below 100 hour MA.
§ 01 Executive Snapshot What: President Trump's financial disclosure reveals significant income from
investinglive.com